CRISPR Therapeutics (CRSP)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Gene Editingsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-01. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 15/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 19.86% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
- CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?
- CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
- CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As Book Value Questions Linger
- Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
- CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
- CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
- CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Advancements in CRISPR-based in vivo gene therapy for hemophilia. — Front Genome Ed 2026 PMID 42787633
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for CRISPR Therapeutics.
Full CRSP Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.